Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Advisory Committees Just Can’t Say “No”

Executive Summary

Who says an advisory committee stop is a risky proposition? FDA’s advisors have voted in favor of approval on each of the last 12 products they’ve reviewed.

You may also be interested in...



Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments

After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.

Can A Safety Study Support A Superiority Claim? Barely, FDA Advisors Say

FDA advisory committee narrowly endorses CV mortality benefit claim for Boehringer/Lilly's diabetes drug Jardiance, but some panelists question wisdom of relying on study originally designed for cardiovascular safety to support a post-marketing superiority claim.

Clovis Pulls Plug On Rociletinib On Expected FDA Rejection

Clovis Oncology Inc. on May 5 disclosed the FDA notified the company to expect its application for its experimental lung cancer drug rociletinib to be rejected – something that was widely expected on Wall Street after the firm failed in April to convince a federal panel of experts to back the medicine. Clovis, which is cutting its staff by 35% in the wake of the FDA's snub, now turns its attention to its investigational ovarian cancer drug rucaparib.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119020

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel